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ABSTRACT 
Glioblastoma multiforme (GBM) is the most aggressive and most common 
primary brain tumor in adults accounting for 50-60% of primary brain tumors. The 
prognosis for patients with GBM remains poor and treatment is mainly palliative 
with a mean survival time of less than one year. Radiotherapy is used extensively in 
the management of glioblastoma either alone or in combination with surgery and/or 
chemotherapy. However, this tumor is one of the most resistant tumors to 
radiotherapy thus limiting the benefit of this form of treatment.  
 
Studies have shown that malignant tumors have a high content of glutathione 
an antioxidant responsible for protecting the cells against damage from free radicals 
(mainly superoxide, hydroxyl and hydrogen peroxide). It is well established that 
glutathione, by neutralizing these free radicals plays a major role in radioresistance. 
Glioblastoma has relatively high levels of glutathione. In this study, by reducing the 
glutathione content of glioblastoma in a rat model, we were able to investigate the 
effect of this reduction in enhancing the effect of radiotherapy as a form of treatment 
for glioblastoma multiforme in a rat model.   
 
By injecting L-Buthionine-SR-Sulfoximine (BSO) in to the tumor tissue, the 
glutathione content of the tumor was reduced by about 70% of its initial value. When 
administered into the tumors 2 hours prior to radiotherapy the animals so treated had 
a significantly longer median survival time compared with animals that received 
radiotherapy alone. 
 
 
 
 
 
 
     ii
ACKNOWLEDGEMENTS 
I would like to thank my supervisors Drs Robert Griebel and Bernhard Juurlink 
for accepting my proposal and for giving me an opportunity to explore my research 
potential. Their warm and friendly attitude in supervising my work and support in 
every possible way made all the difference and served as a valuable experience. 
I am very grateful to Dr Roger Keith who as the Head of Department of 
Surgery was very welcoming and gladly accepted me into his department. I am also 
grateful to the members of my advisory committee Drs Andy McFadden, Daryl 
Fourney and H. Vachhrajani for their valuable time and constructive criticism and 
guidance in the preparation of this thesis.  
I would also like to express my gratitude to Dr Narinder Sidhu of the 
Saskatoon Cancer Centre for administering radiotherapy to both the cell cultures and 
animals. I am also thankful to Dr Rob Ottani and Mrs Alain Lalonce and John Cook of 
the Department of Medical Imaging for the MRI imaging of the animals. 
I am also thankful to the secretaries of the Department of Surgery Ms Kathy 
Kaleen and Ms Jody Garnett and to Ms Karen Bader the Postgraduate program 
administrator for their friendly attitude and prompt action on all issues relating to my 
research work. I am also grateful to Mr Lloyd Balbuena for giving me hand with some 
of the statistical analysis. 
I would also like to than Dr Elisabeth Schültke with whom I shared the same 
office and who has been very instrumental in most of my research work. Her input in 
is greatly appreciated. 
I am also thankful to the secretary of the department of Anatomy and Cell 
Biology Ms Shirley West who was very kind and helpful. I am also very thankful to 
Ms Connie Wong for helping me with the cell culture techniques and preparation of 
different growth media. I am also grateful to Ms Arlene Drimmie who helped me in 
conducting HPLC. I also feel greatly indebted to Ms Mehri Herman who helped me 
with taking care of the animals. 
     iii
I would also like to thank my friends and colleagues Drs Adebola Obayan, 
Hortense Nsoh-Tabien, Hossein Noyan Ashraf and Viktor Sirkhar. We shared lots of 
thought provoking discussions and helpful tips along the way. 
I am also grateful to Saskatchewan Synchrotron Institute for awarding me a 
graduate student scholarship that allowed me to combine my thesis research with 
synchrotron research and provide a unique opportunity of exploring the exciting world 
of this high tech research as applied to biological sciences and its potential in brain 
tumor imaging and treatment using an animal model. 
Last but not least I would like to thank my beautiful wife Ms Aldodahia 
Magzoob for her patience and understanding and unconditional support throughout my 
period of study and to our son Awab (Shabaka) and daughter Amna (Nana) who had to 
cope with my long hours of absence during the preparation of my thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     iv
DEDICATION 
To my mother Nima Abdelraheem and my father Ali Ataelmannan  
Who inspired and supported me in every step of my pursuit of knowledge.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     v
TABLE OF CONTENTS 
 
PERMISSION TO USE .....................................................................................................i 
ABSTRACT .......................................................................................................................ii 
ACKNOWLEDGEMENTS ............................................................................................ iii 
DEDICATION ...................................................................................................................v 
TABLE OF CONTENTS .................................................................................................vi 
HYPOTHESIS ...................................................................................................................1 
1. Introduction ...................................................................................................................2 
2. Literature Review ..........................................................................................................8 
2.1 Glutathione...............................................................................................................9 
2.2 Biosynthesis and Degradation ................................................................................9 
2.3 Biological Functions of Glutathione.....................................................................11 
2.4 Antioxidant Activities............................................................................................12 
2.5 Modulation of the Immune System ......................................................................12 
2.6 Detoxification .........................................................................................................12 
2.7 Glutathione and Cancer ........................................................................................13 
2.8 Glutathione and Cancer Therapy ........................................................................13 
2.9 Chemical Depletion of Glutathione......................................................................14 
2.10 Types of GSH Depleting Agents .........................................................................15 
2.10.1 Substrates of Glutathione Transferases .............................................................15 
2.10.2 Oxidants.................................................................................................................16 
2.10.3 Inhibitors of Biosynthesis.....................................................................................16 
2.10.4 Miscellaneous Compounds ..................................................................................17 
2.11 Choice of Depleting Agent ..................................................................................17 
2.12 L-Buthionine –SR-Sulfoximine (BSO)...............................................................17 
2.13 Routes of BSO Administration ...........................................................................18 
2.14 BSO in Human Studies .......................................................................................18 
 
3. Materials and Methods ...............................................................................................20 
Cell Culture Experiment.............................................................................................21 
3.1 Tissue Culture ........................................................................................................21 
3.2 Addition of BSO.....................................................................................................21 
3.3 Cell Harvesting and GSH Measurement .............................................................22 
3.4 C6 Experimental Groups ......................................................................................22 
     vi
3.5 Transport of Cell Cultures ...................................................................................23 
3.6 Irradiation of C6 Cell Cultures ............................................................................24 
3.7 Cell Counting .........................................................................................................25 
Animal Experiment .....................................................................................................26 
3.8 Intracranial Implantation.....................................................................................26 
3.9 MRI of Tumor Harboring Rats............................................................................27 
3.10 Glutathione Estimation .......................................................................................27 
3.11 Radiotherapy for Rats.........................................................................................28 
3.12 End of Experiment ..............................................................................................28 
3.13 Fixation and H & E Staining of Brain Tissue ...................................................29 
 
4. Results...........................................................................................................................30 
4.1 The Effect of BSO on C6 Glioma Cell Culture ...................................................31 
4.2 Effect of Radiation Therapy on the Growth of C6 Glioma Cells......................32 
4.3 MRI of Rats Following Implantation of C6 Cells...............................................34 
4.4 Effect of BSO on Normal Brain and Brain Tumor ............................................35 
4.5 Survival of Rats Following Treatment ................................................................36 
4.6 Histology .................................................................................................................40 
 
5. Discussion .....................................................................................................................42 
5.1 Choice of Animal Tumor Model ..........................................................................43 
5.2 Choice of Radiosensitizing Agent .........................................................................43 
5.3 Effect of BSO on Cell Culture ..............................................................................43 
5.4 Effect of RT and BSO on C6 Cell Culture ..........................................................44 
5.5 Route of BSO Administration to Animals...........................................................45 
5.6 Survival Outcomes and Statistical Analysis ........................................................45 
5.7 Conclusion ..............................................................................................................47 
 
6. References ....................................................................................................................48 
 
 
 
 
 
 
 
 
     vii
LIST OF FIGURES 
 
Fig 2.1: The structure of glutathione (gamma-glutamyl-cysteinyl-glycine) 
Fig 2.2: Pathway for glutathione biosynthesis. 
Fig 2.3: Functions of glutathione. 
Fig 3.1:  Flushing the transport chambers with 5% carbon dioxide in air. 
Fig 3.2: C6 culture plates being placed for irradiation with 10 Gy. 
Fig 3.3: A rat placed in a sterotaxic frame under general anaesthesia prior to                
implantation of C6 glioma cells.  
Fig 4.1: GSH levels of C6 Glioma cells following 24 hour exposure to BSO. 
Fig 4.2: Effect of radiation therapy (10 Gy) on C6 cell growth over 48 hour period. 
Fig. 4.3: Coronal (A) and axial (B) T-2 weighted MRI scans showing the presence of a         
tumor in the brain of a Wistar rat 13 days post implantation of C6 cells. 
Fig 4.4: Coronal T-2 weighted MRI scans showing the tumor (A) and dilated lateral 
ventricle (B) in the brain of Wistar rat 18 days post implantation of C6 cells. 
Fig 4.5: Time-dependent effect of BSO on normal brain and tumor tissue GSH. 
Fig. 4.6: Survival curve of animals following different forms of treatment 
Fig. 4.7: Survival function for the effect of radiotherapy on survival of rats 
Fig. 4.8: Survival function for the effect of BSO on survival of rats 
Fig. 4.9: Section of a rat’s brain (H&E stain) at 13 days post implantation of C6 cells. 
Fig 4.10: H & E stain of a rat’s brain that at 26 days following C6 cells implantation.    
Fig 4.11: H & E stain of a rat’s brain that was treated with radiotherapy and BSO at 
100 days following C6 implantation.  
 
 
 
 
     viii
LIST OF ABBREVIATIONS 
 
ATP                                     Adenosine Triphosphate 
BBB                                     Blood Brain Barrier 
BCNU                                 1,3-Bis(2-Chloroethyl)-1-Nitrosourea 
BSO                                     L-Buthionine- SR-Sulfoximine  
CCDP                                  cis-Dichlorodiammineplatinum (II) 
CED                                     Convection Enhanced Delivery 
DEM                                    Diethyl Maleate 
DMEM                                 Dulbecco’s Modified Eagle’s Medium  
DNA                                     Deoxyribonucleic Acid 
EDTA                                   Ethylene Diamine Tetraacetic Acid 
GBM                                    Glioblastoma Multiforme  
GPX                                     Glutathione Peroxidase  
GSH                                     L-glutamyl-L-cysteinylglycine  
GSSG                                   Oxidized-Glutathione  
H & E                                   Hematoxylin and Eosin 
HPLC                                   High-performance liquid chromatography 
H2O2                                                       Hydrogen Peroxide 
MRI                                      Magnetic Resonance Imaging 
PBS                                      Phosphate Buffered Saline 
ROS                                     Reactive Oxygen Species 
RT                                        Radiotherapy 
SOD                                     Superoxide Dismutase  
     ix
HYPOTHESIS 
 
 
Reducing the cellular content of tumor glutathione in a rat glioma model using  
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Brain tumors are the most common solid tumors in children and the second 
most common malignancy of childhood (1). In North America and Western Europe 
there are about 6-11 new cases of primary intracranial tumors per 100,000 per year  in 
men and 4-11 new cases in women (2, 3). Asian populations have a lower incidence 
rate than Europe and North America (3). The incidence in developing countries is 
lower but this may be due to under reporting (4). However, Caucasians tend to have a 
higher incidence when compared to people of African or Asian origin (5, 6) and thus 
there may be ethnic differences in susceptibility to brain tumors. The incidence of 
glioblastoma and germ-cell tumors is 3.5 times more frequent in Caucasians than in 
African Americans (7).  
Some studies have shown an increase of about 1-2% per year in the incidence 
of brain tumors during the 1980s and1990s (8) both in the elderly (9) and in children 
(10). However this increase may be due to introduction of better diagnostic techniques 
which have greatly improved diagnosis of neurological diseases (11). In some of the 
Scandinavian countries, increased incidence was  seen in the late 1970s and early 
1980s a period which coincided with introduction of improved diagnostic methods 
(12). After  the 1980s the incidence for both sexes remained relatively stable (12). 
In North America  and Western Europe the mortality rates from nervous 
system tumors  are approximately 4–7 per 100,000 person per year in men and 3–5 in 
women (3, 13). The mortality and incidence rates in both sexes show similar patterns 
worldwide.  Changes in ratio between incidence and mortality in different regions 
usually reflect differences in the success of disease management (13) The survival of 
glioma patients (with exception of pilocytic astrocytoma) is still very poor (14). For 
glioblastoma patients, the  5-year survival rate is less than 3% (15, 16). Older age at 
diagnosis is a poor prognostic factor for both sexes (16).   
Primary glioblastoma arise de novo and account for 60% of cases in adults 50 
years of age and older (17). They usually manifest clinically in less than 3 months. 
Secondary glioblastoma account for the remainder and are typically seen in younger 
patients, usually less than 45 years. They develop through malignant progression from 
a low-grade astrocytoma (grade II or III). The time required for this progression 
ranges from 1 to 10 years, with a mean interval of 4-5 years.   
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Primary brain tumors are classified according to the tissue from which they 
arise. The most common are gliomas which arise from tissue that supports and 
nourishes the brain, the glial tissue. They account for about 45-50% of all primary 
brain tumors and include astrocytomas, oligodendrogliomas, and tumors with mixtures 
of two or more of these cell types (17). The microscopic appearance of brain tumors is 
used to grade brain tumors from I to IV to indicate their level of malignancy with 
grade IV being the most malignant with a tendency to invade normal surrounding 
brain tissue and a potential for local spread. These are known as glioblastoma 
multiforme and account approximately for 50% of astrocytomas. Grade III 
astrocytomas grow more rapidly than lower grade tumors and tend to invade normal 
surrounding brain tissue. Grades I & II astrocytomas account for 25-30% of all 
gliomas and are the least malignant of the astrocytomas although they do have the 
potential to progress to higher grade astrocytomas. 
Glioblastoma primarily affect adults and they are located preferentially in the 
subcortical white matter of the cerebral hemispheres. They may affect the brain stem 
in children and the spinal cord, but this is much less common. These tumors are 
composed of poorly differentiated astrocyte cells with a high mitotic index and a 
necrotic centre.  To maintain their rapid growth, the tumors induce new blood vessel 
formation. These tumors may develop from lower-grade astrocytomas (grade II) or 
anaplastic astrocytomas (grade III) but more commonly arise de novo without any 
evidence of an antecedent lesion (17). 
The treatment of GBM remains a great challenge with current therapies being 
mainly palliative and no significant advances during the last two decades (18, 19). 
Without therapy patients usually die within three months while patients treated with 
optimal therapy have a median survival of approximately 1 year (20). However, a 
recent study using radiotherapy plus concomitant and adjuvant Temozolomide showed 
an increase in the median survival of patients to 14.6 months as compared to 12.1 
months when using radiotherapy alone after a follow up of 28 months (21). 
One of the great difficulties in treating GBM arises from the fact that the tumor 
cells have an infiltrative nature with no clear border around them. Cancer cells may 
spread throughout the brain and further away from the site of the bulk tumor. Even in 
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cases where radical surgery can be performed it is impossible to get a clear margin 
with complete eradication of the tumor (19). 
The treatment of GBM involves a combination of surgery, radiotherapy and 
chemotherapy. Surgery helps to alleviate some of the patient’s symptoms by 
decreasing the raised intracranial pressure. It also aims to remove all tumor tissue 
without causing neurological deficit. However, this is usually not feasible and may be 
compromised by the location of the tumor as well as its infiltrative nature. Overall, the 
survival of patients with GBM who undergo surgery as the only form of treatment is 
on average approximately 14 weeks (17, 22). 
Radiotherapy after surgery helps prolong the survival of patients. Even when it 
appears that the entire tumor has been surgically removed, microscopic cancer cells 
remain in the surrounding brain tissue or at distant sites from the bulk tumor. 
Radiation targets the residual tumor with the goal of reducing its size or stopping its 
progression. If the entire tumor cannot be removed safely, postoperative radiotherapy 
is often recommended. Radiotherapy is also used instead of surgery for inaccessible 
GBM. The initial approach to treating gliomas with radiotherapy was whole-head 
irradiation. This was later abandoned due to the substantial neurological deficits that 
resulted, sometimes appearing a considerable time after treatment. Current clinical 
practice uses a more focused radiation field that includes only 2-3 cm beyond the 
periphery of the tumor site.  
In many instances, radiotherapy can induce a phase remission often marked 
with stability or regression of neurological deficits as well as a reduction in size of the 
tumor. However, the response of GBM to radiotherapy varies. Combining 
radiotherapy with surgery results in a median survival of 40 weeks (17, 22). Radiation 
therapy therefore prolongs survival and improves quality of life over the intermediate 
period of time. This is followed by a further clinical deterioration and eventually leads 
to the demise of the patient. In recurrent GBM the mortality rate approaches 100% 
within a few weeks to months. Following the diagnosis of recurrence, a reasonable 
quality of life is usually limited to 10 weeks in these group of patients (23). 
The use of brachytherapy (a form of radiotherapy in which a radioactive source 
is placed in or near the tumor) or radiosurgery (a form of non-invasive brain surgery in 
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which focused radiation beams are delivered to a specific area of the brain to be 
treated) in treatment of gliomas has been one of the major advances in the treatment of 
these tumors using radiation therapy. Median survival time for patients receiving 
brachytherapy has been 18-20 months (24). Unfortunately, due to restrictions because 
of tumor size and location, only 25-40% of patients are eligible to receive this form of 
treatment. Those who receive the treatment had a median survival of 16 months as 
compared to 6 months for those who did not. However, selection bias was thought to 
be the reason for this apparent benefit of brachytherapy (25). Phase III clinical trials 
that used random assignment of patients who met the inclusion criteria for 
brachytherapy versus a control failed to show a statistically significant benefit of 
brachytherapy, although there was a numerical advantage for patients receiving 
brachytherapy (26, 27).  
A popular alternative to brachytherapy is radiosurgery using either a linear 
accelerator or the Gamma Knife. Radiosurgery, unlike brachytherapy which requires 
surgery and 5-7 days of treatment sessions, does not require surgery and can be 
conducted in a single treatment session. It is also associated with a lower rate of 
radiation necrosis. However, some studies have indicated that there is no difference in 
benefit between the two forms of treatment, at least for recurrent GBM (28). Some 
centers use fractionated radiosurgery for the treatment of larger tumors. This consists 
of one radiation session per week for four weeks. However, different studies have 
shown this form of treatment to have conflicting results when compared to single 
radiation sessions ranging from being similar to very positive (29, 30). 
Chemotherapy has been of slight benefit in increasing survival of patients with 
GBM (31). Chemotherapy may be given before, during or after radiation therapy. It is 
often administered at the time of tumor recurrence. The response rate to most of the 
chemotherapeutic agents used is no greater than 30-40% and most fall into the range 
of 10-20% (32). Patients receiving RT alone have a two-year survival rate of 0-10% as 
to compared to a survival rate of 15-25% for patients receiving a combination of 
radiotherapy and chemotherapy (33). 
Radiation therapy is still used extensively in the management of glioblastoma. 
However, one of the major limitations of this form of treatment, is the intrinsic or 
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acquired resistance of this tumor to radiation therapy whether used alone or in 
combination with surgery (34). Exposure of cells to ionizing radiation causes the 
formation of reactive oxygen species (ROS), mainly superoxide, hydroxyl radical and 
hydrogen peroxide inside the cells. This is thought to be one of the main mechanisms 
by which ionizing radiation causes cell damage and death. Antioxidant enzymes such 
as superoxide dismutase (SOD), catalase and glutathione peroxidase (GPX) can be 
used to eliminate ROS in cells. This diminishes the action of ionizing radiation and 
protects the cell against cell damage. It is also known that these antioxidant enzymes 
play a role in radioresistance and chemoresistance. Glioblastoma which is on the most 
radioresistant tumors has  relatively high levels of these enzymes (35). 
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2.1 Glutathione 
Glutathione (L-glutamyl-L-cysteinylglycine; GSH) is a tri-peptide composed 
of three amino acids: glutamic acid, cysteine and glycine. Glutathione is essential to 
all life and is found in tissues of virtually all plants and animals at an intracellular 
concentration of 1–10 mM in mammalian cells (36). In 1888 while working with yeast 
cells de Rey-Pailhade found out that yeast cells contain a substance that is responsible 
for forming hydrogen sulfide when the cells were crushed with elemental sulfur. He 
also found the same substance to be present in a number of plant and animal tissue 
including beef liver, sheep brain, fish muscle, egg white and freshly picked aspargus. 
de Rey-Pailhade named this substance philothion (from the Greek “sulfur loving”). In 
1921 Hopkins renamed philothion as glutathione (37). It has been estimated that more 
than 90% of the nonprotein sulfur of cells is in the form of glutathione (38).   
 
     
 
          Fig 2.1: The structure of glutathione  
 
2.2 Biosynthesis and Degradation 
GSH is synthesized from L-glutamate, L-cysteine, and L-glycine by the 
consecutive action of γ-glutamylcysteine synthetase and GSH synthetase in two ATP 
(or energy requiring) dependent reactions (39). The first reaction is the rate-limiting 
step and is effectively inhibited by GSH feedback. However, when GSH is oxidized, 
feedback inhibition is lost and the availability of L-cysteine as a precursor can become 
the rate-limiting factor (40). Once GSH is produced, it will either function by itself or 
be degraded to participate in other metabolic pathways such as the γ-glutamyl cycle 
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that can supply amino acid precursors for GSH synthesis (39). The enzymes involved 
in GSH degradation are γ-glutamyl transpeptidase and dipeptidases.  
Under normal conditions, the majority of glutathione exists in reduced form (GSH). 
Oxidation of the GSH to form oxidized-glutathione (GSSG) is carried out either by 
direct interaction with free radicals or more often when GSH acts as a cofactor for 
antioxidant enzymes such as GSH peroxidases during the reduction of H2O2 (both 
selinium-dependent and non-selinium-dependent forms) and phospholipid 
hydroperoxide GSH peroxidases. The ratio of the GSSG/GSH couple can serve as an 
important indicator of the cellular redox environment.  
 
 
                              
          
Fig 2.2: Pathway for glutathione biosynthesis. 
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2.3 Biological Functions of Glutathione 
Glutathione has a number of cellular functions. It is an effective intracellular 
reducing agent. It functions in catalysis, metabolism, and transport as well as 
protection of cells against foreign compounds, free radicals and reactive oxygen 
compounds. GSH is also an active participant in reactions that destroy hydrogen 
peroxide and organic peroxides. It also protects DNA from free-radical damage. 
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   Fig 2.3: Functions of glutathione. 
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2.4 Antioxidant Activities 
Aerobic metabolism in aerobic organisms leads to oxygen radical stress as a 
byproduct. This results in the formation of highly active intermediates, namely 
hydrogen peroxide and superoxide which promote further oxygen radical production 
that lead to cellular damage (41). Being the major endogenous soluble antioxidant in 
mammalian cells, GSH provides protection against this oxidative stress. It functions as 
a substrate for the antioxidant enzymes GSH peroxidase and phospholipid 
hydroperoxide GSH peroxidase that convert peroxides into less harmful alcohols, 
water and GSSG (42). GSH can directly scavenge radicals and peroxides via mixed 
disulfide formation or upon oxidization to GSSG and thus protect the cells against 
oxidative stress by a non-enzymatic action. This prevents the harmful effects on 
tissues associated with peroxidation of cell membrane lipids (43). There is evidence 
that a variety of oxygen radical stresses can result in depletion of GSH and formation 
of GSSG the short term (44). 
 
2.5 Modulation of the Immune System 
GSH is required in the normal function of the immune system and production 
of an immune response. Intracellular GSH has been shown to modulate T-cell 
function, including the binding, internalization, and degradation of interleukin-2 (45). 
It is also important for DNA synthesis (46). GSH can also enhance cytotoxic T-cell 
activation, proliferation and differentiation (47). Studies have shown not only that in 
vivo administration of GSH can activate cytotoxic T-cells, but also that depletion of 
intracellular GSH can inhibit the activation of lymphocytes, suppressing their 
cytotoxic functions and increasing susceptibility of the cell to radiation damage (48). 
 
2.6 Detoxification 
Mammalian cells are involved in many metabolic activities and are thus 
exposed to many chemical toxins such as heavy metals and drug metabolites. They are 
also exposed to physical damage caused by environmental pollutants, smoke and 
ultraviolet radiation. All these physical and chemical toxins lead to cellular damage, 
and if left unchecked can eventually lead to cellular death. There are cellular 
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mechanisms which are responsible for detoxification and counteracting these 
damaging effects. These mechanisms include phase I reactions (which can lead to 
either to activation or inactivation of a drug), hydrolysis or reduction and phase II 
reactions which involve the conjugation of toxins to endogenous chemicals with little 
or no chemical activity. A major phase II reaction in mammalian cells is conjugation 
to GSH. This is particularly important in the detoxification of electrophilic substances 
such as epoxides, alkenes, halides and heavy metals (49). Organs that have the highest 
exposure to toxins such as the lungs, liver and kidneys are the richest in GSH. 
Elimination of GSH conjugates takes place via an ATP-dependent glutathione S-
conjugate export pump called GS-X pump (50). 
 
2.7 Glutathione and Cancer 
GSH has a complex role in both protection of cells against cancer and cancer 
therapy. While GSH plays an important role in the detoxification of carcinogens and 
protection of cells against cancer development, it is elevated  in many types of tumors 
where it is thought to play an important role in increased resistance of these tumors to 
chemo- and radiotherapy (51-54). Such elevated  levels are seen in many cancer 
tissues including breast, lung, colon, ovary, liver and larynx (55-63). 
 
2.8 Glutathione and Cancer Therapy 
Free radicals can cause cell injury and other pathologies including cancer if 
they are not neutralized. Intracellular GSH helps to counteract the effect of these free 
radicals thereby protecting the cells against potential damage. While increasing GSH 
levels within normal cells may help protect the cells against damage and development 
of cancer due to free radicals, many studies have employed various methods to reduce 
GSH in cancer cells in an attempt to make them more susceptible to chemotherapy and 
radiotherapy. Some studies have shown that by using BSO to reduce the GSH in cell 
culture lines, different responses to chemotherapy in normal versus tumor cells with 
the tumor cells lines being more susceptible (64, 65).  
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2.9 Chemical Depletion of Glutathione 
Tissue glutathione levels are intentionally altered for various experimental 
studies. Different cell populations in a given organ may not necessarily have the same 
GSH concentration and there may be discrete subcellular pools of GSH (66, 67). 
Studies have shown that depletion of tissue glutathione by more than 70% of normal 
values can lead to changes in xenobiotic metabolism (deactivation and secretion of 
foreign chemicals such as drugs which happens mostly in the liver) and increased 
toxicity of electrophilic metabolites. Depletion of hepatic GSH in rats resulted in 
increased toxicity of acetaminophen (68) with similar effects observed in mice (68), 
goats (69) and hamsters (70). 
Different methods are used to lower GSH levels. One of the methods used is 
the administration of compounds that react enzymatically with GSH to form 
conjugates. Depletion of GSH can also be achieved by inhibition of GSH synthesis in 
organs with a high turnover rate. Another method for GSH depletion is conversion of 
GSH to its oxidized form, GSSG. However, the choice of depleting agent depends on 
what system is being studied e.g. in the liver where glutathione transferase levels are 
high, compounds whose reaction with GSH is enzyme-catalyzed will be more 
effective. For the same reason, such compounds are more effective in rodents than 
rabbits or monkeys with lower transferase concentration (71). In the kidneys which 
have a high GSH turnover rate, inhibitors of GSH synthesis are most effective (72) 
while in organs or cells with high concentrations of microsomal monooxygenases, 
depleting agents requiring activation by these enzymes are the most effective. 
When choosing a depleting agent, other than the efficacy of the agent in 
depleting GSH, its side effects must also be taken into consideration. Many GSH 
depleting agents can result in lipid peroxidation and cell lysis in isolated liver cells 
(73) and in animals so treated, an increased rate of lipid peroxidation was observed 
with liver homogenates probably resulting from GSH depletion (74). 
Tissue GSH levels are lowered by many electrophillic chemicals by reacting 
with the sulfhydryl group of GSH. By covalently binding nonselectively to 
nucleophiles, some highly electrophilic compounds can cause toxic effects. This 
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makes compounds that react moderately and which require enzymatic catalysis to 
produce GSH depletion a much better choice. 
 
2.10 Types of GSH Depleting Agents 
Based on their mechanism of action substances that bring about glutathione 
depletion are divided into different groups: 
 
2.10.1 Substrates of Glutathione Transferases 
These include α,β-unsaturated carbonyl compounds which are weak 
electrophiles. In the presence of glutathione transferases they react with GSH to bring 
about its depletion (75). Diethyl maleate (DEM) is the most widely used compound in 
this group (76). Administration of DEM intraperitoneal reduces hepatic GSH levels in 
rats to less than 20% of control values in 30 minutes with its effect lasting for 2 to 4 
hours (74, 75, 77, 78). The GSH concentrations in the rat red blood cells, kidney, lung 
and brain are also depleted though to a lesser extent than in the liver (79). GSH levels 
in liver, kidney and skin were reduced by repeated topical application of DEM to mice 
(80). DEM has also been used invitro to remove GSH from rat liver and isolated rat 
hepatocytes (68, 81). In addition to GSH depletion, DEM produced a other undesirable 
effects such as increased bile flow in rats and dogs (77) and increased hepatic 
microsomal heme oxygenase activity in rats (82).  
Phorone (diisopropylidene) is another α,β-unsaturated carbonyl compound that 
can be used to produce GSH depletion (83). Phorone when given to rats 
intraperitoneally resulted in depletion of hepatic GSH to less than 10% of control 
levels in 2 hours. However it may cause hepatotoxicity. Acrylonitrile (76), acrylamide 
(79), and esters of acrylic acid (76) are also other unsaturated compounds that can 
deplete GSH by enzyme-catalyzed reactions. Other compounds that can cause GSH 
depletion by enzyme-catalyzed reactions include aliphatic halo compounds such as 
iodomethane (84), aromatic halo compounds such as 1-chloro-2,4-dinitrobenze (85), 
epoxides such as styrene oxide (86) and organophosphates such as the anticancer drug 
BCNU (carmustine) (87). 
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By metabolism to reactive electrophiles, some relatively inert compounds can 
cause tissue depletion of GSH. Acetaminophen (88),  bromobenzene (89), fluoroxene 
(90) and doxorubicin are examples of such compounds. However, these compounds 
can cause hepatotoxicity if excess levels remain after GSH has been depleted. 
 
2.10.2 Oxidants 
Compounds that oxidize GSH to GSSG have been used mainly to deplete GSH 
in in vitro (Latin: within the glass) cell preparations. The main agents in this class are 
diazenecarboxylic acid derivatives such as diamide (91). One of such compounds, 
sodium tetrathionate has been used to deplete GSH in vivo, resulting in diminished 
kidney, erythrocyte and liver GSH levels in rats to values ranging between 15 to 60% 
of control levels in 2 to 5 hours (79); however, these compounds are nephrotoxic. 
 
2.10.3 Inhibitors of Biosynthesis 
Intracellular glutathione is normally maintained within a certain range that may 
vary from one cell or tissue type to another. In this state of equilibrium, GSH 
biosynthesis is balanced by rate of its utilization.  Increasing the rate of GSH 
utilization or decreasing its biosynthesis will result in decreased GSH levels. 
Methionine sulfoximine inhibits two enzyme systems - glutamine synthetase and -
glutamylcysteinesynthetase (92). Thus both glutamine and GSH levels were depleted 
when mice were treated with methionine sulfoximine. This resulted in both 
convulsions and death in the treated mice (92, 93). In search for a more specific 
inhibitor of glutamylcysteine synthetase, different methionine sulfoximine analogs 
was synthesized and evaluated both in vitro and in vivo. The most specific inhibitor of 
glutamylcysteine synthetase was found to be L-buthionine sulfoximine (BSO) (94). 
Furthermore, unlike its higher analogs such as hexathionine and heptathionine which 
are quite toxic, BSO was found to have no toxic effects even when administered in 
very high concentrations  (92, 94, 95). The toxic effects of the higher analogs is 
thought to be due to non-specific membrane damage or due to insolubility of these 
compounds at physiologic pH (92). 
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2.10.4 Miscellaneous Compounds 
There are a number of compounds whose mechanism of action is unknown and 
which do not fit into any of the above groups but can also cause depletion of GSH in 
cells or tissues. Ethylmorphine is one of such compounds. It causes depletion of GSH 
in isolated rat hepatocytes (73).  Aspirin also caused reduction of rat hepatic GSH 
levels to about 70% of control levels in 4 hours when given intraperitoneal. (96). 
Fasting also leads to depletion of hepatic GSH. When fasted for 18 hours rats had 
significantly lower hepatic GSH levels than fed controls. However, GSH levels in the 
kidney, brain and erythrocytes were not significantly affected (79). 
 
2.11 Choice of Depleting Agent 
The choice of a chemical for lowering GSH has to take into account the 
efficacy of the compound as well as its unwanted side effects. The site of action of the 
depleting agent is also very important as not all depleting agents cause GSH depletion 
in all tissues. Substrates of glutathione transferases can only act where these enzymes 
are present such as the liver and kidney. DEM is a powerful compound for depleting 
hepatic GSH in vivo and has few undesirable effects. Also α,β-unsaturated carbonyl 
compounds have powerful GSH depletion action but not much is known about their 
undesirable side effects. On the other hand, buthionine-SR-sulfoximine (BSO) is a 
powerful depleting agent with very high efficacy and very few if any harmful side 
effects. It can also cause depletion in almost all tissues where GSH is synthesized. 
 
2.12 L-Buthionine –SR-Sulfoximine (BSO) 
BSO is a synthetic amino acid that depletes glutathione irreversibly inhibiting 
gamma-glutamylcysteine synthetase, the rate limiting enzyme in glutathione synthesis. 
BSO competes with glutamate for the same binding site. As such, the rate and extent 
of BSO inhibition depends on the concentration of glutamate. Adding 10 µM BSO  in 
presence of 5 mM glutamate and 10 mM ATP, led to 100% inhibition of γ-
glutamylcysteine synthetase in rat kidney in 10 minutes (97). Buthionine sulfoximine 
inhibits GSH biosynthesis by effectively inhibiting γ-glutamylcysteine synthetase, the 
rate limiting enzyme in GSH biosynthesis (68).  
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2.13 Routes of BSO Administration 
BSO can be administered in various ways to bring about GSH depletion. The 
most commonly used routes are oral and intraperitoneal. Both methods can produce 
very high level of GSH depletion. However, both methods also cause wide spread 
GSH depletion with some organs such as the liver affected more than others. Other 
organs such as the brain are only slightly affected. This global depletion of GSH 
which is not confined to one site can cause alterations in the overall homeostasis of the 
animal. Thus, both routes can not be used to produce depletion at one site alone. 
Convection enhanced delivery (CED) is a relatively new method of delivering 
drugs directly into the brain or the spinal cord. This method bypasses the BBB (blood 
brain barrier) ensuring maximum delivery of the drug to the brain. The BBB is a 
membranic structure composed of endothelial cells that are very tightly packed in 
brain capillaries. This arrangement restricts the passage of substances from the blood 
to the brain much more than endothelial cells in capillaries elsewhere in the body. By 
this method, high local concentrations of the drug can be achieved without affecting 
the overall metabolism of the animal. Furthermore the procedure has been shown to be 
very safe in animals and humans as well (98). 
 
2.14 BSO in Human Studies 
Two human ovarian cancer cell lines (KK and MH) from the ascites of patients 
who did not respond to the anticancer agent cisplatin (CDDP)-based combination 
chemotherapy were found to contain higher than normal levels of glutathione. These 
cells were resistant to the drug CDDP in a manner corresponding to the level of 
intracellular glutathione. Preincubating these cells with BSO resulted in reduction of 
cellular glutathione to 9-25% of initial values. Incubating the cells with 10 µM BSO, 
the cells were sensitized to CDDP and its analogues showing a decrease of 79-38% in 
the IC50 (a measure of drug effectiveness) values (99). In another study, the effect of 
reducing glutathione using BSO on the cytotoxicity of cisplatin, carboplatin and 
radiation in human stomach cancer cell line (SNU-1) and ovarian cancer cell line 
(OVCAR-3) was analyzed. It  was found that BSO effectively depleted the 
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intracellular glutathione concentration and enhanced the effect of both the drugs and 
radiation (100). 
BSO has also been used to deplete glutathione in humans for enhancing the 
effect of cytotoxic drugs. In a phase 1 clinical trial, patients were given BSO in two 
cycles consisting of BSO alone intravenously every 12 hours for six doses and 1 week 
later the same BSO as cycle one with melphalan (LIPAM) 15 mg/m2 intravenous one 
hour after the fifth dose. Doses of BSO were escalated from 1.5 to 17g/m2. Using this 
regime, the only toxicity that was attributable to BSO was grade I or II 
nausea/vomiting in half of the patients. When glutathione content in mononuclear cells 
(PMN) and tumor tissues were measured at intervals following BSO administration, it 
was found that GSH content decreased over 36 to 72 hours reaching its lowest levels 
on day 3 when PMN glutathione levels were approximately 10% of control at BSO 
doses of 7.5 g/ m2. Also at BSO doses of 13g/m2 or more tumor GSH was reduced to 
about 20% of starting values on the third day in 5 out of 7 patients. The study also 
found that total-body clearance (CLt) and volume of distribution at a steady state (Vss) 
was dose dependent for both R- and S-BSO. The harmonic half lives for R-BSO and 
S-BSO were 1.39 hours and 1.89 hours respectively. The biomedically appropriate 
dose of BSO was found to be 13g/m2 (101).  
BSO is also used in a phase II clinical trial at McGill Centre for Translational 
Research in Cancer to measure the activity of intravenous melphalan (L-PAM) with 
BSO in patients with ovarian cancer refractory to taxol combination. In the trial 
patients will receive a continuous infusion of BSO for 48 hours. Melphalan is then 
administered and BSO infusion continued for another 24 hours. This is repeated every 
3-4 weeks while the tumor is followed up using tumor measurements and tumor 
markers to evaluate the response to therapy. The study is ongoing and some promising 
responses have been observed in the patients studied so far (A Phase II Trial of IV-L-
PAM and BSO in Patients with Relapsed or Refractory Ovarian Cancer: 
www.mctrc.org/en/rp/studies/bso.htm 
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3. Materials and Methods 
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Cell Culture Experiment 
3.1 Tissue Culture 
The C6 glioma cell line was obtained from the American Type Culture 
Collection. This line was produced by in random-bred Wistar-Furth rats by exposure 
to N,N – nitrosmethylurea (102). The cells are stored in the laboratory of Anatomy 
and Cell Biology in liquid nitrogen from where they were taken out and thawed by 
warming for 30 seconds in a water bath at 37oC while shaking moderately. The cells 
were then suspended in Dulbecco’s modified eagle’s medium (DMEM) with 15% 
heat-inactivated fetal bovine serum (FBS) and 0.2 mM glutamine, 50 µg/ml neomycin 
and 100 mg/l streptomycin and cultured on 100 mm Falcon tissue culture plates. Five 
x 105 C6 glioma cells were planted into each culture plate. The cultures were 
maintained for 48 hours in an incubator under an atmosphere of 5% CO2 and 95% air 
at temperature of 37 °C.  
Cultures were examined daily for the morphology and color of the medium as 
well as density of the cells. Three days following planting of cells the culture medium 
was replaced by a new growth medium to ensure that cells receive adequate nutrition. 
During the first 48 hours the C6 cells go through a lag phase during which there is 
minimal or no growth before going into the exponential growth phase when they have 
a high metabolic rate as well as increased proliferation rate. The cells finally enter a 
stationary phase when the cells become confluent on the culture plates and there is no 
room for further expansion (103).  
  
3.2 Addition of BSO  
On the third day after cell planting, BSO was added to the growth medium at 
concentrations of 1, 10, 100 and 1000 µM respectively. No BSO was added to the 
control group. There were a total of 10 cell culture plates with two per group. The 
BSO was reconstituted by dissolving in sterile water the powder form of BSO 
(C8H18N2O3S) stored at 2 – 8 ºC. First a stock of 10 mM BSO is made and further 
concentrations were made using the formula C1V1 = C2V2 to obtain the required 
concentration. The working concentration was then added to the culture plates which 
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were then returned to the incubator and allowed to stand for 24 hours before 
measuring GSH concentration. 
 
3.3 Cell Harvesting and GSH Measurement 
GSH concentration of the cells was measured using the monochlorobimane 
method as outlined in Kamencic et al (104). First the cell cultures were inspected 
under the microscope to make sure they were healthy and growing well. The growth 
medium was then exchanged with a serum free medium (without FBS) and 100 µM of 
monochlorobimane added. After 30 minutes the cells were washed with phosphate 
buffered saline (PBS) twice. Ethylene diamine tetraacetic acid (EDTA) was used to 
detach the cells from the culture plates. They were then washed with a Puck’s solution 
before adding harvesting medium. Cultures were then returned to the incubator and 
left for 30 minutes under the same conditions to allow them to detach from the culture 
plates and became rounded. Manual washing of the cells using a pipette was then done 
to ensure all cells were detached before being transferred to a culture tube. They were 
then spun for 10 minutes at 1000 rpm. The supernatant was discarded and replaced 
with Hank’s solution. The cells were then sonicated for 5 s thrice. This was followed 
by centrifugation at 13000 g for 10 minutes. The supernatant was aspirated and its 
glutathione content of the samples and standards were measured using a fluorimeter 
(Fluoroskan Ascent® from Thermo Scientific) at the City Hospital Saskatoon.   
 
3.4 C6 Experimental Groups 
To study the effect of radiotherapy on the C6 glioma cells, the cells were 
planted in 100 mm plates as described above. They were divided into three groups 
with 12 culture plates in each group. The first group acted as a control group. The 
second group received radiotherapy only while the third group received BSO and 
radiotherapy. BSO was added as described above at a concentration of 100 µM 
solution 24 hours prior to radiotherapy. Each group was further divided into three 
subgroups that were harvested at 2, 24 and 48 hours following treatment. Each 
subgroup consisted of 4 culture plates. The cultures were maintained at the specified 
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conditions above at the Department of Anatomy and Cell Biology Central Tissue 
Culture Laboratory.  
 
3.5 Transport of Cell Cultures 
Transportation of the culture plates from the Department of Anatomy and Cell 
Biology to the Cancer Clinic was done using modulator chambers. These were 
humidified by placing a water filled Petri dish on the bottom of the incubator chamber. 
The cell culture plates were then placed in the chamber and the chamber continuously 
flushed with 5% CO2 in air for 5 minutes (Fig 3.1). This ensured that cultures were 
maintained within the same pH during the transport time which is approximately about 
7- 10 minutes.  
 
 
                        
 
 
 
Fig 3.1:  Flushing the transport chambers with 5% carbon dioxide. 
 
 
 
     . 
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3.6 Irradiation of C6 Cell Cultures 
Radiation therapy was done at the Department of Radiotherapy of the 
Saskatoon Cancer Clinic. A single dose of 10 Gy was administered to each cell culture 
plate (Fig 3.2). Irradiation was of photon type at 150 KeV. There is about +/-5% 
variation of radiation dose throughout the irradiation field. All 36 plates of C6 glioma 
cell cultures were irradiated. 
 
 
                           
             
Fig 3.2: C6 culture plates being placed for irradiation with 10 Gy. 
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3.7 Cell Counting 
Cells were isolated from the tissue culture dishes using harvesting medium as 
described above and then counted using a hemocytometer at 2, 24 and 48 hours 
respectively following radiotherapy. Nigrosin-containing solution was added in a ratio 
of 1:4 to the cell suspension (Nigrosin 0.03% concentration in a balanced salt solution 
is used as a dye in this method. Live cells do not take up this dye while dead cells, due 
to loss of the semipermeable membrane take up the dye and stain black). The two 
were gently mixed and allowed to stand for 15 minutes. A small amount was 
transferred to one side of the hemocytometer while the cover slip was in place. This 
was done by carefully touching the edge of the cover slip with the tip of the pipette 
and allowing each chamber to fill by capillary action. Starting with one chamber of the 
hemocytometer cells were counted in the 1 mm centre square and four 1 mm corner 
squares using a 100X light microscope magnification. A separate count of viable and 
dead cells was kept. Cells on top and left touching middle line were included while 
those touching middle line at bottom and right were excluded from the count. Four 
corner squares in one chamber were counted and the average was calculated. Each 
large square of the cover in place represents a volume of 0.1 mm3 or 10-4 cm3. Since 1 
cm3 is approximately equal to 1 ml, the total number of cells per ml was determined 
using the formula: 
Cells/ml = average cell count per square x dilution factor x 104  
Total cells were then calculated by multiplying the cells/ml by the original volume of 
cells from which the sample was taken. 
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Animal Experiment 
To study the effect of BSO on the animal model glioma adult male Wistar rats 
weighing 250-300 gm were used for the experiments and were obtained from Charles 
River, St Constant, Quebec. In the first experiment, the effect of BSO on normal brain 
and tumor tissue was evaluated. In the second experiment the effect of RT and BSO in 
treating the tumor harboring rats was studied. For both experiments, the animals had 
intracranial implantation of the C6 glioma cells. Prior to implantation, C6 cells were 
cultured and harvested in the same way described above. They were then resuspended 
in Hanks solution and constituted to a concentration of 10 x 104 cells/µl of solution. 
They were then ready to be implanted into the brain.  
 
3.8 Intracranial Implantation  
The Animal Ethics Committee of University of Saskatchewan approved this 
experimental protocol. Rats were anesthetized with halothane using an anesthetic 
machine before positioning on a stereotaxic frame (Fig. 3.3). The hair was shaved and 
the head cleaned with iodine and alcohol. A skin incision of about 1.5 cm in length 
was made in the mid-line starting behind the eyes and extending backwards. A burr 
hole was made about 2.5 mm behind the coronal suture and about 2.5 mm to the right 
of the midline using a small drill MiniMite® from Dremel. C6 cells were then 
implanted using a 27 G needle attached to a Hamilton syringe. The syringe was 
attached to the stereotaxic frame and using a micropump, 10 µl of aliquot containing 
100,000 cells were injected to a depth of 4mm at a rate of 2 µl per minute. The burr 
hole was then sealed with bone wax and the incision closed. Subcutaneous 
buprenorphine (Buprenex) was administered to relieve pain. This was diluted with 
normal saline in a ration of 1:5 and given at a dose of 0.05 mg/kg. After recovering 
from anesthesia the rats were returned to their housing facility. They were followed up 
for a period of 13 days during which they were monitored for any symptoms and were 
weighed 3 times weekly.  
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Fig. 3.3: A rat placed in a sterotaxic frame under general anaesthesia prior to  
implantation of C6 glioma cells. 
 
3.9 MRI of Tumor Harboring Rats 
On the 13th day following implantation MRI was conducted on all the rats. 
This was done at the Department of Medical Imaging, Royal University Hospital, 
Saskatoon using a Siemens Symphony 1.5 tesla with Syngo 2002B software. The 
images are Turbo Spin Echo T2 weighted. The rats were sedated using a combination 
of ketamine and xylazine prior to imaging. 
 
3.10 Glutathione Estimation 
On the 14th day after implantation a total of 6 rats were injected with BSO 
using the same set up for C6 implantation. Through the previous burr hole 4µL of       
100 µM BSO was injected to a depth of 3 mm into the tumor tissue using a 
micropump at a rate of 2 µL per minute. The burr hole was then sealed using bone 
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wax. BSO was also injected in to the brain of 6 healthy rats at a site corresponding to 
the site of tumor in the experimental rats. This acted as the control group. Two rats 
each from both experimental and control groups were then sacrificed at 0, 2, and 4 
hours. The tumor tissues was harvested and immediately immersed in liquid nitrogen 
prior to glutathione estimation. The glutathione content of both tumor tissue and 
healthy brain samples was then measured using high-performance liquid 
chromatography (HPLC) according to the procedure outlined in Kamencic et al (105).   
 
3.11 Radiotherapy for Rats 
According to the type of treatment they received, the animals were divided into 
six groups. The first group received BSO and radiotherapy, the second group normal 
saline and radiotherapy, the third group radiotherapy alone, the fourth group BSO 
alone, the fifth group normal saline alone and the sixth group received no treatment 
and was allowed to run the natural course of the disease. There were a total of 30 rats. 
Radiotherapy was administered at the Cancer Clinic at the Royal University Hospital, 
Saskatoon. A single dose of 10 Gray was given using a 16 MeV machine. The rats 
were again sedated using a combination of ketamine and xylazine prior to 
radiotherapy. 
 
3.12 End of Experiment 
Following treatment, animals were returned to their housing facility and 
followed up. Those that became symptomatic were sacrificed when symptoms became 
severe. When no treatment is administered, symptoms of increased intracranial 
pressure usually appear after 18 to 25 days following implantation and consist of 
slowing down of activities, sluggishness and later contralateral hemiparesis. There is 
decreased food intake with loss of weight, impaired grooming and later circling and 
seizures. Without intervention, the rats go on to develop stupor followed by the demise 
of the animal.  Rats were sacrificed once they develop contralateral paralysis, circling 
or seizures. The long term survivors were sacrificed at the end of the experiment 
which was 100 days post implantation of C6 cells. Sacrificing of rats was done by 
trans-aortic perfusion with paraformaldehyde under general anaesthesia.  
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3.13 Fixation and H & E Staining of Brain Tissue 
The whole brain was then removed from the cranium and sectioned into three 
parts before embedding in paraffin using a Tissue-Tek® VIP machine from Miles 
Scientific. The embedded samples were sectioned at 10 µm thickness and mounted on 
Colorfrost™ Plus from Erie Scientific. They were then stained using Hematoxylin and 
Eosin (H&E). Hematoxylin is a base and stains acidic cellular components (mainly 
DNA and RNA) dark blue. Eosin is an acid and stains basic components which 
include most of the cytoplasmic components of the cell pink. 
The protocol used for staining with H & E involves the passage of paraffin 
sections through a series of solutions for specified times. These solutions include 
xylene, absolute alcohol, 95% ethanol, 70% ethanol, and tap water respectively before 
rinsing in distilled water.  The slides are then immersed in Ehrlich’s Hematoxylin for 
10 minutes and rinsed in tap water. They are then dipped 4 times in acid alcohol and 
washed in tap water before immersing in saturated lithium carbonate (1.36 g/100 ml). 
Subsequently, they are rinsed in running tap water followed by distilled water before 
being immersed in Eosin Y solution for 1 minute. They are then removed, rinsed again 
and examined under the microscope to make sure that appropriate amount of staining 
is achieved. The staining was adequate and the slides were then dipped for specific 
times in 95% ethanol, absolute alcohol, absolute alcohol/xylene and finally xylene. 
Finally, in a fume hood Cytoseal was applied to cover slips and then mounted on to 
the slides. The slides were then allowed to dry and were then ready for histological 
examination. 
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4. Results 
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4.1 The Effect of BSO on C6 Glioma Cell Culture  
The addition of BSO to cell cultures led to the reduction of GSH synthesis. 
There was a dose-dependent reduction in GSH levels to a certain concentration.  The 
maximal reduction occurred at a concentration of 100 µM BSO leading to reduction of 
GSH of more than 80% of baseline values. There was no further reduction in GSH 
concentration at a higher concentration of 1000 µM BSO (Fig 4.1). (n = 10, 2 per 
group). 
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Fig 4.1: GSH levels of C6 Glioma cells following 24 hour exposure to BSO. Error bars 
represent standard error of the mean.  
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4.2 Effect of Radiation Therapy on the Growth of C6 Glioma Cells 
After 2 hours from the time of RT, the control group had a mean cell count of 
70.1 ± 2.13 X 104. Following treatment with RT (10 Gy) either alone or in 
combination with BSO the mean cell count was found to be 68.43 ± 5.1 X 104 and 
68.81 ± 4.41 X 104  respectively, with the errors being standard deviations (Fig 4.2).  
 
In the next 24 hours the mean cell count of the control group increased to 
106.87 ± 8.23) X 104. Those that received RT had a similar growth rate with a mean 
cell count of 106.12 ± 11.09 X 104 while the group that received RT and BSO had a 
slower growth rate with a mean cell count of 92.37 ± 9.78 X 104 (Fig 4.2). 
 
At 48 hours the cells in the control group had greatly multiplied to a mean cell 
count of 190.93 ± 5.48 X 104 while both the groups that received either RT alone or in 
combination with BSO had much slower growth rate with a mean cell count of 137.68 
± 9.56 X 104 and 107.93 ± 9.2 X 104 respectively (n = 4 in all groups) (Fig 4.2). 
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Fig 4.2: Effect of radiation therapy (10 Gy) on C6 cell growth over 48 hour period.  
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4.3 MRI of Rats Following Implantation of C6 Cells 
 
All 30 rats were imaged on the 13th day post implantation. MRI confirmed the 
presence of tumor in all the rats that had been implanted with C6 glioma cells (e.g. Fig 
4.3 & 4.4). 
 
  
A B
 
Fig. 4.3: Coronal (A) and axial (B) T-2 weighted MRI scans showing the tumor in the 
brain of a Wistar rat 13 days post implantation of C6 cells. 
R 
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Fig 4.4: Coronal T-2 weighted MRI scans showing the tumor (A) and dilated lateral 
ventricle (B) in the brain of Wistar rat 18 days post implantation of C6 cells. 
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4.4 Effect of BSO on Normal Brain and Brain Tumor 
The glutathione concentration of normal brain tissue was found to be 31.65 
nmole/mg protein (SD = 0.25) while that of tumor tissue was found to be 44.18nmole/mg 
protein (SD = 2.0). Injection of BSO into the brain and tumor tissue resulted in decrease 
of GSH concentration in both the normal brain and tumor tissue. The effect was maximal 
at 2 hours with normal brain GSH reduced to 28.13 nmole/mg protein (SD = 1.8) while 
the glutathione content of the tumor tissue was reduced to 11.37 nmol/mg protein (SD = 
4.0) (Fig 4.5). 
Time (Hours)
420
M
ea
n 
M
ea
n 
G
SH
 C
on
ce
nt
ra
tio
n 
(n
m
ol
/m
g 
pr
ot
ei
n)
50.00
40.00
30.00
20.00
10.00
0.00
Tumor
Normal
tiss_type
 
          
Fig 4.5: Time-dependent effect of BSO on normal brain and tumor tissue GSH. Error 
bars are one standard error of the mean 
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4.5 Survival of Rats Following Treatment  
Rats that received no form of treatment (n = 4) had a median survival time of 
16 days. Those that received BSO (n = 4) and normal saline (n = 4) as the only form of 
treatment had a median survival time of 18 days and 22 days respectively. The rats 
that received radiotherapy as the only form of treatment (n = 6) or a combination of 
normal saline and RT (n = 6) had a longer median survival time of 40 days for RT 
alone and 35 days for normal saline and RT alone respectively. Rats that had BSO and 
RT as a form of treatment had 4 out of 6 rats surviving at the end of 100 days 
compared to one surviving rat out of each of the 6 rats that received either RT alone or 
in combination with normal saline (Fig. 4.6). 
Using Cox regression analysis the effect of radiotherapy and BSO on the 
survival of rats was analyzed. The odds of survival for those that had radiotherapy is 
12.8 (95% confidence interval 3.7 to 44.3) times greater compared to those that had no 
radiotherapy in their treatment (p < 0.001) (Fig. 4.7). Rats that had BSO incorporated 
in their treatments had an odds of survival of 2.88 (95% confidence interval 1.09 to 
7.64) times greater compared to those that had no BSO at all (p < 0.05). The 2 factors 
combined are significant predictors of survival (p < 0.001) (Fig. 4.8). 
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  Fig. 4.6: Survival curve of animals following different forms of treatment. 
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Fig. 4.7: Survival functions for the effect of radiotherapy on survival of rats. 
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Fig. 4.8: Survival functions for the effect of BSO on survival of rats. 
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4.6 Histology  
All 24 rats that had become symptomatic were euthanized. At the end of 100 
days post implantation of C6 cells, 6 rats were still surviving. These were also 
euthanized at this time. Histological analysis of the brains of all 30 rats was carried out 
to look for the presence of tumor cells. The C6 cells are injected into the cerebral 
cortex at a depth of 4 mm. At 13 days post implantation, the tumor is fairly large and 
deeply situated within the cortex (c) (Fig. 4.10). At this stage the tumor can be easily 
visualized on MRI scans. It effects on the surrounding brain can also been seen on the 
histological slide with slight dilatation of the ipsilateral lateral ventricle (v). Parts of 
the tumor have infiltrated into the deeper structures across the corpus callosum (cc) 
and into the thalamus (t). At this stage however, no gross changes are visible on the 
contralateral side.  
 
     
c
cc
 
Fig. 4.9: Section of a rat’s brain (H&E stain) at 13 days post implantation of C6 cells. 
The dark staining tumor can be seen in the right cortex with some projections into the 
thalamus. A magnification of the tumor cells is shown on the right.  
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At 26 days post implantation, the tumors are very large with massive 
infiltration into the brain tissue. Most of the ipsilateral cerebral cortex is destroyed by 
tumor tissue with crossing of the midline into the contraleral cortex. The ventricles are 
grossly dilated and there is substantial invasion of the thalamus by tumor tissue. At 
this stage the rat is usually very symptomatic and had to be euthanized. 
 
          
Fig 4.10: H & E stain of a rat’s brain 26 days post implantation showing the extent of 
tumor growth. The region in the box is magnified on the right depicting the tumor cells. 
 
           
Fig 4.11: H & E stain of a rat’s brain implanted with C6 glioma cells that was treated 
with RT and BSO at 100 days following treatment. To the right is a magnification of the 
region of tumor cell implantation. No tumor cells could be detected. 
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5. Discussion 
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5.1 Choice of Animal Tumor Model  
C6 cell transplanted in Wistar and Sprague-Dawley rats were found to have 
characteristics closer to natural glioblastoma in humans than tumor grown in other 
strains of rats (106). When injected intracranially at a total number of  100,000 cells, 
there was a 100% take with the cells growing in a predictable fashion and the tumor 
was consistently lethal in non-radiated animals (107). The tumor’s glial nature, its 
stability in tissue culture and its consistent ability to grow intracranially in the Wistar 
rat made this a good model for this study. There was a 100% uptake of tumor in our 
animal models as confirmed by MRI.  
5.2 Choice of Radiosensitizing Agent 
Aerobic metabolism in organisms leads to oxygen radical stress as a 
byproduct. This results in the formation of highly active intermediates, namely 
hydrogen peroxide and superoxide that promote oxygen radical production which 
leads to cellular damage and increased production of oxygen free radicals (41). Being 
the major endogenous soluble antioxidant in mammalian cells, GSH provides 
protection against this oxidative stress (42)-(43).  The various functions of GSH have 
been previously outlined. 
Different methods have been used to lower GSH levels. However, each method 
has its own drawbacks mainly in the form of unwanted side effects which can be quite 
serious in some instances ranging from nephrotoxicity to convulsions and death with 
certain compounds. BSO was found to have no side effects when administered to 
animals. In humans, the only side effects observed were nausea and vomiting and a 
slight decrease in white cell count (101).  No side effects were observed in the animals 
that were given BSO (92, 94, 95). 
 
5.3 Effect of BSO on Cell Culture 
The reduction in GSH concentration correlates with findings in other studies 
where BSO was used to reduce GSH levels. Beyond 100 µM solution of BSO no 
further dose dependent GSH reduction was seen. This is due to the fact that BSO acts 
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as a competitive inhibitor of γ-glutamyl-cysteine synthase and at this concentration 
saturation occurs. 
 
5.4 Effect of RT and BSO on C6 Cell Culture 
The effect of radiotherapy is achieved mainly by causing the tumor cells to 
lose their ability to reproduce and thus cause a gradual reduction in tumor size. Thus 
as time goes on, more and more cells are lost as they try to divide and multiply. In 
certain cases, the aim is to cause tumor ablation altogether using higher doses. The 
effect on tumor growth is brought about by damage to the cell DNA. This is induced 
either by primary photons or charged particles from the radiation source causing direct 
damage to the DNA or by the formation of free radicals and other oxidants due to 
interactions within the cell. These free radicals and oxidants in turn cause DNA 
damage and are toxic to the cell. 
After 2 hours following radiotherapy either alone or in combination with BSO, 
there was no significant difference in the cell count of all three groups. This shows 
that there was no direct killing effect of radiation such as seen with very high doses of 
irradiation. After 24 hours, there was some difference in cell count between the 
groups. While the group that received both RT and BSO showed the smallest increase 
in cell proliferation, the effect was minimal and not statistically significant.  
After 48 hours however the difference in cell proliferation was more marked. 
While the control group continued to grow in an exponential fashion, both the two 
other groups were growing at a much slower rate.  Cells that received RT alone 
showed a significant difference ( p < 0.05) in cell number compared to the control 
group while those that received a combination of RT and BSO showed an even greater 
slowing down in cell proliferation ( p < 0.001). BSO in combination with RT was 
superior in arresting cell proliferation (and hence causing cell death) compared to RT 
alone with the difference being statistically significant (p < 0.05). 
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5.5 Route of BSO Administration to Animals 
BSO can be administered in various ways to bring about GSH depletion. The 
most commonly used routes are oral and intraperitoneal. Both methods can produce 
marked reduction in the level of intracellular GSH. However, both methods also cause 
wide spread GSH depletion with some organs such as the liver being affected more 
than others. Other organs such as the brain are only slightly affected. This widespread 
depletion of GSH which is not confined to one site can cause alterations in the overall 
homeostasis of the animal. These routes are thus unsuitable to bring about GSH 
depletion in the brain alone.  
In Convection-enhanced delivery (CED) a drug can delivered locally into the 
brain using a positive pressure gradient or bulk flow. It also allows the blood brain 
barrier (BBB) to be bypassed ensuring maximum delivery of the drug to the brain. By 
this method high local concentrations of a drug can be achieved without affecting the 
overall metabolism of the animal (98). The procedure has been shown to be very safe 
in rat tumor models (108). We thus preferred this method to administer BSO and 
induce GSH depletion in the brain tumors of the rats. The BSO administered was quite 
effective in reducing the GSH level in the tumor but had little effect in normal brain 
tissue. As previously cited BSO acts mainly on actively dividing cells where there is 
new production of glutathione. In normal brain, where there is little or no cell division 
taking place, the effect of BSO is very minimal. 
 
5.6 Survival Outcomes and Statistical Analysis 
A total of 30 rats were used for this experiment. Survival times were 
determined from the day of tumor implantation to the day of euthanasia. Euthanasia 
was done when symptoms which included weakness, tremors, loss of weight and 
circling became severe enough to prevent the animal from moving around and feeding. 
From our experience animals that are not sacrificed at this point usually died a day 
later and thus one day was added to all the animals that were euthanatized due to these 
symptoms. The Statistical Package for the Social Sciences (SPSS) program was used 
and survival data were analyzed using Kaplan-Meier test. 
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When rats that were allowed to run the natural course of the disease were 
compared to those that received BSO or normal saline as the only form of treatment, 
there was no statistically significant prolongation in the median survival time of any of 
the two groups (p < 0.2 & 0.5) respectively. This showed that neither BSO nor normal 
saline on their own had any effect in changing the course of the disease in the rats. 
When compared with those that had no treatment, rats that received RT alone 
had a statistically significant (p < 0.048) increase in median survival time. The 
survival of rats that had a combination of normal saline and radiotherapy was the same 
as those that received radiotherapy alone (p < 0.86). Normal saline has no known 
radiosensitizing effect on malignant tumors. Thus the combination therapy using 
normal saline and radiotherapy had a similar outcome to that of radiotherapy alone. 
The difference in survival times between rats that received a combination of 
BSO and RT and the group that received no treatment at all was highly significant (p < 
0.001). When compared with animals that received RT alone there is a marked 
difference (p < 0.059). The effect of radiotherapy across all groups in which it was 
administered was analyzed using Cox regression. Those that received radiotherapy 
were about 12.8 times more likely to survive compared to those that did not receive 
radiotherapy either alone or in combination (p < 0.001). This is expected since 
radiotherapy is the main treatment modality for this type of tumor. For rats that 
received BSO compared to those that did not the survival probability was much less 
being 2.88 (p < 0.05).  This shows that while BSO on its own had little impact on the 
outcome of the tumors, it did have some beneficial effect which could be attributed to 
its antioxidant properties as previously discussed. The combined effect of radiotherapy 
and BSO in predicting survival outcome was highly significant (p < 0.001). 
Four rats out of 6 were still surviving at the end of 100 days among those that 
received a combination of BSO and radiotherapy compared to 1 rat each in the groups 
that received radiotherapy alone and a combination of radiotherapy and normal saline. 
It is not surprising to have a long term survivor among rats that received radiotherapy 
alone since cure of many cancers can be achieved using this form of treatment even 
though this form of cancer is not know to be curable by radiation alone. The 
combination of normal saline and radiotherapy had no additional effect on long term 
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survival compared to radiotherapy alone and this too is expected as normal saline is 
not a know radiosensitizer. However, the combination of BSO and radiotherapy as a 
form of treatment for this cancer is highly superior when compared to radiotherapy 
alone as shown by the median survival times of animals in both groups as well as the 
number of animals still surviving at the end of the study.  
 
5.7 Conclusion 
The role of BSO in enhancing the effect of chemotherapeutic drugs has already 
been established as evidenced by the ongoing phase II clinical trial using a 
combination of BSO and IV-L-PAM in the treatment of patients with relapsed or 
refractory ovarian cancer at the McGill Centre for Translational Research in Cancer 
(MCTRC). This study showed that the effect of radiotherapy in treating glioblastoma 
in an animal model can be significantly enhanced by using BSO as a radiosensitizing 
agent. It is possible that following further studies and evaluation, this form of 
combination treatment could play a significant role in the ongoing battle against this 
highly malignant form of brain tumor.  
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